Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00337207
Other study ID # NU 05C3
Secondary ID NU-05C3STU000052
Status Completed
Phase Phase 2
First received
Last updated
Start date March 2006
Est. completion date May 2009

Study information

Verified date January 2020
Source Northwestern University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor.

PURPOSE: This phase II trial is studying how well bevacizumab works in treating patients with recurrent or progressive glioma.


Description:

OBJECTIVES:

- Determine the safety of single-agent bevacizumab in the treatment of patients with recurrent or progressive malignant glioma.

- Determine the efficacy of bevacizumab, in terms of progression-free survival at 6 months, in these patients.

- Assess changes in tumoral blood flow based on magnetic resonance (MR) perfusion and tissue changes by MR spectroscopy.

OUTLINE: This is a pilot study.

Patients receive bevacizumab IV over 30-90 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically.

PROJECTED ACCRUAL: A total of 55 patients will be accrued for this study.


Recruitment information / eligibility

Status Completed
Enrollment 55
Est. completion date May 2009
Est. primary completion date November 2008
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility DISEASE CHARACTERISTICS:

- Histologically confirmed malignant glioma, including the following:

- Glioblastoma multiforme

- Gliosarcoma

- Anaplastic astrocytoma or anaplastic glioma

- Malignant glioma not otherwise specified

- Evidence of tumor recurrence or progression by MRI or CT scan with contrast

- CT scan or MRI must be performed = 96 hours post-operatively (= 2 weeks prior to study registration) or 4-6 weeks post-operatively to assess residual disease in patients who have undergone recent resection of recurrent or progressive tumor

- Steroid dosage must have been stable for = 5 days

- Failed = 1 prior systemic treatment with chemotherapy or biologic agents (excluding polifeprosan 20 with carmustine implant [Gliadel wafers])

- Failed prior external-beam radiotherapy

- If received prior interstitial brachytherapy or stereotactic radiosurgery, true progressive disease (rather than radiation necrosis) must be confirmed by positron emission tomography, single-photon emission computer tomography with thallium, magnetic resonance (MR) spectroscopy, MR perfusion, or surgical documentation

PATIENT CHARACTERISTICS:

- Karnofsky performance status 70-100%

- Life expectancy > 8 weeks

- WBC > 3,000/mm³

- Absolute neutrophil count > 1,500/mm³

- Platelet count > 100,000/mm³

- Hemoglobin > 10 g/dL (transfusion allowed)

- SGOT and SGPT < 1.5 times upper limit of normal (ULN)

- Bilirubin < 1.5 times ULN

- Creatinine < 1.5 mg/dL

- Blood pressure = 150/100 mm Hg

- No unstable angina

- No New York Heart Association class II-IV congestive heart failure

- No stroke or myocardial infarction within the past 6 months

- No clinically significant peripheral vascular disease

- No evidence of bleeding diathesis or coagulopathy

- Urine protein:creatinine ratio < 1.0

- No significant medical illness that would preclude study participation or cannot be adequately controlled with appropriate therapy

- No other serious medical illness or infection

- No disease that would obscure toxicity or dangerously alter drug metabolism

- No significant traumatic injury within the past 28 days

- No abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within the past 6 months

- No serious, nonhealing wound, ulcer, or bone fracture

- No history of any other cancer (except nonmelanoma skin cancer or carcinoma in situ of the cervix) unless cancer is in complete remission and patient is off all therapy for that cancer for = 3 years

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

PRIOR CONCURRENT THERAPY:

- See Disease Characteristics

- More than 4 weeks since prior surgery for recurrent or progressive disease and recovered

- More than 28 days since prior major surgical procedure or open biopsy

- At least 4 weeks since prior cytotoxic therapy (6 weeks for nitrosoureas)

- At least 2 weeks since prior vincristine

- At least 3 weeks since prior procarbazine hydrochloride

- At least 1 week since prior noncytotoxic agents (e.g., interferon, tamoxifen, thalidomide, or isotretinoin)

- Radiosensitizer does not count

- At least 4 weeks since prior experimental biologic agents (e.g., epidermal growth factor receptor [EGFR] inhibitors)

- More than 7 days since prior minor surgery, such as fine-needle aspirations or core biopsies

- No concurrent combination anti-retroviral therapy for HIV-positive patients

- No concurrent enzyme-inducing anticonvulsants (EIACs)

- Patients on EIACs must switch to nonenzyme-inducing convulsants = 2 weeks prior to study enrollment

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
bevacizumab
Bevacizumab 15 mg/kg every 3 weeks over 30 to 90 minutes. One cycle = 3 weeks. Treatment continues until progressive disease or unacceptable toxicity.

Locations

Country Name City State
United States Hematology-Oncology Associates of Illinois Chicago Illinois
United States Robert H. Lurie Comprehensive Cancer Center at Northwestern University Chicago Illinois

Sponsors (2)

Lead Sponsor Collaborator
Northwestern University National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

References & Publications (1)

Raizer JJ, Gallot L, Cohn R, et al.: A phase II safety study of bevacizumab in patients with multiple recurrent or progressive malignant gliomas. [Abstract] J Clin Oncol 25 (Suppl 18): A-2079, 94s, 2007.

Outcome

Type Measure Description Time frame Safety issue
Primary Safety of Treatment Safety of treatment will be defined by the number of patients that experience grade 3 and 4 adverse events where causal relationship with bevacizumab cannot be completely ruled out. Adverse events will be graded using Common Terminology Criteria for Adverse Events v3.0 (CTCAE) where:
Grade 1 Mild AE Grade 2 Moderate AE Grade 3 Severe AE Grade 4 Life-threatening or disabling AE Grade 5 Death related to AE
From treatment initiation, throughout treatment and up to 30 days post-treatment, for up to 1 year.
Primary Progression-free Survival at 6 Months The number of patients experiencing progression free survival (PFS) was calculated at the 6-month time point. After all patients have surpassed the 6 month post-treatment timepoint
Primary Tumoral Blood Flow Changes To assess changes in tumoral blood flow based on MR Perfusion and tissue changes by MR spectroscopy. Before and after treatment
See also
  Status Clinical Trial Phase
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Completed NCT00006080 - Fenretinide in Treating Patients With Recurrent Malignant Glioma Phase 2
Recruiting NCT00887146 - Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma Phase 3
Suspended NCT00935090 - 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer N/A
Completed NCT00621686 - Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme Phase 2
Terminated NCT00227032 - Erlotinib in Treating Patients With Progressive Glioblastoma Multiforme Phase 1
Completed NCT00112502 - Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme Phase 2
Terminated NCT00243022 - Dietary, Herbal and Alternative Medicine in Glioblastoma Multiforme Phase 2
Active, not recruiting NCT00087815 - Hyperbaric Oxygen Therapy in Treating Patients With Radiation Necrosis of the Brain N/A
Active, not recruiting NCT00278278 - Combination Chemotherapy and Radiation Therapy With or Without Methotrexate in Treating Young Patients With Newly Diagnosed Gliomas Phase 3
Completed NCT00416819 - Combination Chemotherapy and Rituximab in Treating Patients With Newly Diagnosed Primary CNS Lymphoma N/A
Completed NCT00052286 - Modafinil in Treating Fatigue and Behavioral Change in Patients With Primary Brain Cancer N/A
Completed NCT00006093 - EMD 121974 in Treating Patients With Progressive or Recurrent Glioma Phase 1/Phase 2
Recruiting NCT00004129 - Phosphorus 32 in Treating Patients With Glioblastoma Multiforme Phase 1
Completed NCT00004212 - DX-8951f in Treating Children With Advanced Solid Tumors or Lymphomas Phase 1
Completed NCT00003417 - Computer Planned Radiation Therapy Plus Chemotherapy in Treating Patients With Glioblastoma Multiforme Phase 1/Phase 2
Completed NCT00003173 - High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors Phase 2
Completed NCT00003020 - LMB-7 Immunotoxin in Treating Patients With Leptomeningeal Metastases Phase 1
Completed NCT00008008 - Thiotepa Followed by Peripheral Stem Cell or Bone Marrow Transplant in Treating Patients With Malignant Glioma Phase 2
Completed NCT00003484 - Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors Phase 1